Tango Therapeutics, Inc. 8K

Tango Therapeutics reported promising Phase 1/2 data and an accelerated development strategy for its PRMT5 inhibitor vopimetostat in combination with RAS(ON) inhibitors in MTAP‑deleted pancreatic and lung cancers, positioning the regimen for potential pivotal trials and future approvals.

Tango Therapeutics used this Form 8‑K investor presentation (Exhibit 99.2) to disclose updated clinical data for its PRMT5 inhibitor vopimetostat in combination with RAS(ON) inhibitors daraxonrasib and zoldonrasib, showing high objective response rates and durable disease control in MTAP‑deleted second/third‑line pancreatic ductal adenocarcinoma and non‑small cell lung cancer, along with a generally manageable safety profile and a strategy to accelerate registration‑directed development in front‑line pancreatic cancer while maintaining a cash runway into 2028. The company highlighted an overall 92–93% ORR in early vopimetostat + daraxonrasib cohorts and 52% ORR with vopimetostat + zoldonrasib in KRAS G12D PDAC, aggregating to a 64% ORR across 2L/3L PDAC patients, and outlined plans to design a Phase 3 first‑line pancreatic cancer trial, explore accelerated second‑line approval pathways, and prioritize capital allocation to PRMT5/RAS combination programs based on its $380 million cash balance as of March 31, 2026.

Filing Facts

CIK

1819133

Ticker

TNGX

Form

8K

Source Type

sec

Accession

0001193125-26-260679

Alert Tier

6